La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Harmony Biosciences Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Harmony Biosciences Hldgs..

Harmony Biosciences Hldgs (NASDAQ:HRMY) Azioni, Catena delle Opzioni

HARMONY BIOSCIENCES HOLDINGS

Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Harmony Biosciences Hldgs

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Holdings Inc

Press Releases

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

HRMY

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

ATAI Life Sciences

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

BGM Group

Bausch Health Companies Inc. Common Stock

Bausch Health Companies

Belite Bio, Inc - American Depositary Shares

Belite Bio

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

LENZ Therapeutics

Liquidia

Maze Therapeutics

Nuvation Bio

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pharvaris

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Comments

Harmony Biosciences Hldgs

Harmony Biosciences Hldgs (HRMY) Opzioni

Harmony Biosciences Hldgs (NASDAQ:HRMY) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO